(Q43202670)

16 November 2017

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study (English)

1 reference

16 November 2017

D A Cameron

1

1 reference

16 November 2017

M C Cornbleet

2

1 reference

16 November 2017

R M Mackie

3

1 reference

16 November 2017

J A Hunter

4

1 reference

16 November 2017

M Gore

5

1 reference

16 November 2017

B Hancock

6

1 reference

16 November 2017

J F Smyth

7

1 reference

16 November 2017

Scottish Melanoma Group

8

1 reference

16 November 2017

language of work or name

English

0 references

publication date

1 May 2001

1 reference

British Journal of Cancer

16 November 2017

1 reference

16 November 2017

84

1 reference

16 November 2017

9

1 reference

16 November 2017

1146-1149

1 reference

https://scigraph.springernature.com/pub.10.1054/bjoc.2000.1623

16 November 2017

0 references

cites work

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363881

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363881

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363881

Interferons in the treatment of malignant melanoma. A review of recent trials

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363881

Cutaneous malignant melanoma, Scotland, 1979-89. The Scottish Melanoma Group

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2363881

Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up

25 May 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11379605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/11379605

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1054/BJOC.2000.1623

1 reference

Dimensions Publication ID

16 November 2017

0 references

1 reference

16 November 2017

PubMed publication ID

11379605

1 reference